2024-09-20 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases. 

**Performance Analysis:**

**1. Relative Performance:**
* **Cumulative Return:** REGN: 116.18%, VOO: 128.99%
* **Relative Performance (vs. VOO):** -12.81% (57.55% percentile)

Regeneron has underperformed the S&P 500 (VOO) over the past period.  The relative performance is currently in the 57.55% percentile, meaning it has outperformed the S&P 500 in 57.55% of past periods within the data set. 

**2. Recent Price Movement:**
* **Closing Price:** $1138.81
* **5-Day Moving Average:** $1149.84
* **20-Day Moving Average:** $1166.91
* **60-Day Moving Average:** $1114.34

The current price is below the 5-day, 20-day, and 60-day moving averages, indicating a potential downward trend.  

**3. Technical Indicators:**
* **RSI:** 32.81 (Below 50, indicating possible oversold condition)
* **PPO:** -0.56 (Negative, indicating potential bearish sentiment)
* **Delta_Previous_Relative_Divergence:** -8.66 (Negative, indicating short-term bearish trend)
* **Expected_Return:** 16.84% (Potential 5-year return based on current investment)

The RSI is currently below 50, indicating a possible oversold condition. The PPO is negative, suggesting bearish momentum. The negative Delta_Previous_Relative_Divergence reinforces the short-term bearish trend. The potential 5-year return based on current investment is 16.84%.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report (2024-08-01) showed an EPS of 13.25, exceeding analyst expectations of 11.50. Revenue of 3.55 B$ also surpassed the expected 3.25 B$. This strong performance suggests positive growth and profitability for Regeneron. 

**5. Summary:**

Regeneron Pharmaceuticals (REGN) has underperformed the S&P 500 recently, though it's currently experiencing a possible oversold condition.  Recent price movements suggest a potential downward trend, which is further supported by the technical indicators. However, the strong most recent earnings report suggests a positive outlook for the company's growth and profitability.

**6. Recommendation:**

Regeneron Pharmaceuticals Inc. is a promising company with a strong track record of success in the biotechnology industry. While the recent price performance has been subdued and technical indicators suggest a potential downward trend, the strong earnings performance and positive outlook provide a potential buying opportunity for long-term investors with a high-risk tolerance. 

**Disclaimer:** This information is for informational purposes only and should not be considered as investment advice. Please consult with a financial professional for personalized investment recommendations. 
